Incyte to Acquire Medicxi-backed Villaris Therapeutics for Auremolimab
Shots:
- Villaris to receive $70M up front, ~$310M upon achievement of development & regulatory milestones along with ~$1.05B in commercial milestones on net sales of the product. Incyte gets an exclusive global right to develop & commercialize auremolimab for all uses, incl. vitiligo & other autoimmune and inflammatory diseases
- The acquisition will complement Incyte’s existing inflammation & autoimmunity portfolio to advance the treatment options for vitiligo patients with potential applications for auremolimab beyond dermatology
- Auremolimab (VM6) is an anti-IL-15Rβ mAb & is expected to enter clinical development in 2023. In preclinical studies, auremolimab showed a high potency, selectivity & efficacy in vitiligo
Ref: Businesswire | Image: Incyte
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
